Loading...
XHKG2186
Market cap1.04bUSD
Dec 27, Last price  
2.15HKD
1D
-0.46%
1Q
-34.85%
Jan 2017
-53.26%
IPO
-67.86%
Name

Luye Pharma Group Ltd

Chart & Performance

D1W1MN
XHKG:2186 chart
P/E
14.27
P/S
1.24
EPS
0.14
Div Yield, %
0.00%
Shrs. gr., 5y
2.96%
Rev. gr., 5y
3.50%
Revenues
6.14b
+2.70%
315,400,000344,368,000308,294,000508,980,000650,976,000954,750,0001,340,895,0001,774,390,0002,135,943,0002,515,111,0003,154,220,0002,563,129,0002,917,794,0003,814,842,0005,173,385,0006,357,596,0005,539,641,0005,200,226,0005,981,656,0006,143,078,000
Net income
533m
-11.94%
71,837,00090,164,00080,912,00058,981,00062,089,000123,547,000136,103,000151,624,000169,032,000310,498,000605,524,000754,523,000891,539,000981,372,0001,303,373,0001,468,562,000706,586,000-144,783,000604,807,000532,605,000
CFO
1.60b
-3.53%
47,990,00042,872,00051,001,000138,506,000105,903,000163,157,000254,209,000325,018,000152,902,000438,618,000319,096,000394,708,000592,028,000964,102,0001,045,587,0001,744,897,0001,033,449,000182,371,0001,653,796,0001,595,487,000
Dividend
Jun 29, 20200.06 HKD/sh

Profile

Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian and breast cancer; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers and other solid tumors; and Xuezhikang, a lipid regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; Rivastigmine Transdermal Patch for the treatment of Alzheimer's disease; Fentanyl Transdermal Patch for cancer pain; Buprenorphine Transdermal Patch for chronic pain; and Seroquel and Seroquel XR for the treatment of schizophrenia and manic episodes of bipolar affective disorders, In addition, the company offers Rykindo, an injection for the treatment of schizophrenia; Tiandixin used as an adjuvant therapy for malignant tumors, hydrothorax and ascites, and respiratory infections; Yitaida for acute promyelocytic leukemia and liver cancer; Lutingnuo, a glutathione injection for toxicity and injuries caused by ionizing radiation; and Beitangning, a pioglitazone hydrochloride capsule to control blood glucose. Further, it offers Nuosen for acute upper digestive tract hemorrhage; Sailimai for the treatment of diarrhea; Apleek Transdermal Patch for contraception; Sidinuo for osteoporosis; Glucosamine hydrochloride tablets for osteoarthritis; Oulai, a compound sodium aescinate gel for local swelling; Oukai for the treatment of soft tissue swelling and venous edema; and Fengshiye for patients who have pains in bones, joints, and limbs. The company distributes and sells pharmaceutical drugs; and manufactures and sells biopharmaceutical products. Luye Pharma Group Ltd. was founded in 1994 and is headquartered in Yantai, the People's Republic of China.
URL
https://www.luye.cn/lvye/
IPO date
Jul 09, 2014
Employees
5,005
Domiciled in
CN
Incorporated in
BM

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
6,143,078
2.70%
5,981,656
15.03%
5,200,226
-6.13%
Cost of revenue
5,225,194
5,101,038
4,762,266
Unusual Expense (Income)
NOPBT
917,884
880,618
437,960
NOPBT Margin
14.94%
14.72%
8.42%
Operating Taxes
161,023
86,466
70,226
Tax Rate
17.54%
9.82%
16.03%
NOPAT
756,861
794,152
367,734
Net income
532,605
-11.94%
604,807
-517.73%
(144,783)
-120.49%
Dividends
Dividend yield
Proceeds from repurchase of equity
922,965
189,156
1,044,477
BB yield
-6.64%
-1.48%
-8.52%
Debt
Debt current
5,195,754
6,839,788
5,263,216
Long-term debt
3,298,839
2,303,222
4,269,527
Deferred revenue
174,965
209,387
Other long-term liabilities
596,221
1,224,970
1,643,127
Net debt
419,724
5,705,186
6,512,296
Cash flow
Cash from operating activities
1,595,487
1,653,796
182,371
CAPEX
(632,656)
(1,163,659)
(1,541,595)
Cash from investing activities
(1,418,258)
(1,658,308)
(3,436,032)
Cash from financing activities
841,599
54,148
1,878,897
FCF
3,142,149
1,415,114
(986,159)
Balance
Cash
6,106,435
5,544,264
5,510,309
Long term investments
1,968,434
(2,106,440)
(2,489,862)
Excess cash
7,767,715
3,138,741
2,760,436
Stockholders' equity
9,369,174
8,244,452
7,677,480
Invested Capital
14,780,947
18,151,112
17,491,702
ROIC
4.60%
4.46%
2.27%
ROCE
4.07%
4.13%
2.16%
EV
Common stock shares outstanding
3,728,363
3,480,853
3,445,431
Price
3.73
1.91%
3.66
2.81%
3.56
-1.66%
Market cap
13,906,793
9.16%
12,739,921
3.87%
12,265,736
6.09%
EV
15,323,826
19,310,875
19,403,812
EBITDA
1,619,735
1,551,931
1,019,942
EV/EBITDA
9.46
12.44
19.02
Interest
675,454
471,755
399,458
Interest/NOPBT
73.59%
53.57%
91.21%